JP2022546101A5 - - Google Patents
Info
- Publication number
- JP2022546101A5 JP2022546101A5 JP2022513645A JP2022513645A JP2022546101A5 JP 2022546101 A5 JP2022546101 A5 JP 2022546101A5 JP 2022513645 A JP2022513645 A JP 2022513645A JP 2022513645 A JP2022513645 A JP 2022513645A JP 2022546101 A5 JP2022546101 A5 JP 2022546101A5
- Authority
- JP
- Japan
- Prior art keywords
- cell preparation
- cells
- modified
- cell
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025185504A JP2026054469A (ja) | 2019-09-01 | 2025-11-04 | リンパ球の改変および送達のための方法および組成物 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894849P | 2019-09-01 | 2019-09-01 | |
| US201962894853P | 2019-09-01 | 2019-09-01 | |
| US201962894852P | 2019-09-01 | 2019-09-01 | |
| US62/894,852 | 2019-09-01 | ||
| US62/894,849 | 2019-09-01 | ||
| US62/894,853 | 2019-09-01 | ||
| US201962894926P | 2019-09-02 | 2019-09-02 | |
| PCT/US2019/049259 WO2020047527A2 (en) | 2018-09-02 | 2019-09-02 | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| USPCT/US2019/049259 | 2019-09-02 | ||
| US62/894,926 | 2019-09-02 | ||
| US201962943207P | 2019-12-03 | 2019-12-03 | |
| US62/943,207 | 2019-12-03 | ||
| US202062985741P | 2020-03-05 | 2020-03-05 | |
| US62/985,741 | 2020-03-05 | ||
| PCT/US2020/048843 WO2021042072A1 (en) | 2019-09-01 | 2020-08-31 | Methods and compositions for the modification and delivery of lymphocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185504A Division JP2026054469A (ja) | 2019-09-01 | 2025-11-04 | リンパ球の改変および送達のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546101A JP2022546101A (ja) | 2022-11-02 |
| JP2022546101A5 true JP2022546101A5 (https=) | 2023-09-08 |
Family
ID=74686079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513645A Pending JP2022546101A (ja) | 2019-09-01 | 2020-08-31 | リンパ球の改変および送達のための方法および組成物 |
| JP2025185504A Pending JP2026054469A (ja) | 2019-09-01 | 2025-11-04 | リンパ球の改変および送達のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185504A Pending JP2026054469A (ja) | 2019-09-01 | 2025-11-04 | リンパ球の改変および送達のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220340927A1 (https=) |
| EP (1) | EP4022035A4 (https=) |
| JP (2) | JP2022546101A (https=) |
| KR (1) | KR20220070449A (https=) |
| CN (1) | CN116057181A (https=) |
| AU (1) | AU2020336230B2 (https=) |
| BR (1) | BR112022003617A2 (https=) |
| CA (1) | CA3152780A1 (https=) |
| MX (1) | MX2022002521A (https=) |
| WO (1) | WO2021042072A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| CN113840911A (zh) * | 2018-09-02 | 2021-12-24 | 埃克苏马生物技术公司 | 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物 |
| WO2021231569A1 (en) * | 2020-05-14 | 2021-11-18 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Dual promoter systems |
| WO2023015310A2 (en) * | 2021-08-06 | 2023-02-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | T-cell manufacturing methods |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4469586A1 (en) * | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| IL320156A (en) * | 2022-10-10 | 2025-06-01 | Kite Pharma Inc | New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection |
| IL326194A (en) * | 2023-07-31 | 2026-03-01 | Bio4T2 Llc | Methods for the expansion and in vivo uptake of CAR cells mediated by blood cells |
| EP4589007A1 (en) * | 2024-01-17 | 2025-07-23 | Revvity Gene Delivery GmbH | Production of viral vectors |
| WO2025213071A1 (en) * | 2024-04-05 | 2025-10-09 | Baylor College Of Medicine | Synthetic gene expression regulatory switches |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022752B1 (ru) * | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| DK3129487T3 (da) * | 2014-04-09 | 2020-11-30 | Dna Twopointo Inc | Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression |
| JP6797803B2 (ja) * | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| US11325948B2 (en) * | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3439675A4 (en) * | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN107400664A (zh) * | 2016-05-20 | 2017-11-28 | 蔡胜和 | 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用 |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| BR112019002035A2 (pt) * | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| IL308824A (en) * | 2016-08-17 | 2024-01-01 | Factor Bioscience Inc | Nucleic acid products and methods of administration thereof |
| WO2018075978A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| EP3735460A4 (en) * | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| CN107988183A (zh) * | 2017-11-17 | 2018-05-04 | 杭州惠博士生物科技有限公司 | 一种重组人透明质酸及其生产方法 |
| CN109913422A (zh) * | 2017-12-13 | 2019-06-21 | 苏州康聚生物科技有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| EP3755347B1 (en) * | 2018-02-21 | 2025-06-25 | Board of Regents, The University of Texas System | Universal antigen presenting cells and uses thereof |
-
2020
- 2020-08-31 US US17/639,281 patent/US20220340927A1/en active Pending
- 2020-08-31 EP EP20857656.1A patent/EP4022035A4/en active Pending
- 2020-08-31 KR KR1020227010243A patent/KR20220070449A/ko active Pending
- 2020-08-31 MX MX2022002521A patent/MX2022002521A/es unknown
- 2020-08-31 CA CA3152780A patent/CA3152780A1/en active Pending
- 2020-08-31 AU AU2020336230A patent/AU2020336230B2/en active Active
- 2020-08-31 CN CN202080076199.XA patent/CN116057181A/zh active Pending
- 2020-08-31 BR BR112022003617A patent/BR112022003617A2/pt unknown
- 2020-08-31 JP JP2022513645A patent/JP2022546101A/ja active Pending
- 2020-08-31 WO PCT/US2020/048843 patent/WO2021042072A1/en not_active Ceased
-
2025
- 2025-11-04 JP JP2025185504A patent/JP2026054469A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546101A5 (https=) | ||
| US11866478B2 (en) | Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor | |
| JP6724009B2 (ja) | 抗ｃｄ７０キメラ抗原受容体 | |
| ES2936474T3 (es) | Construcción del receptor de antígeno quimérico dirigido al antígeno cd20 y actividad identificación de las células T modificadas del mismo | |
| JP2023515211A5 (https=) | ||
| CN112654636A (zh) | 可活化白介素12多肽及其使用方法 | |
| JP2026054469A (ja) | リンパ球の改変および送達のための方法および組成物 | |
| ES2317694T3 (es) | Metodo para inhibir la actividad osteoclastica. | |
| CN112261950A (zh) | 用于治疗cd30+肿瘤的car-cd30 t细胞 | |
| CN111378625A (zh) | 一种cxcl13趋化型car－t细胞的制备和应用 | |
| KR20250024838A (ko) | Kras g12v 돌연변이 폴리펩티드를 표적화하는 t 세포 수용체 및 이의 용도 | |
| CN111850013B (zh) | 一种共刺激受体增效的嵌合抗原受体及其应用 | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| CN120349973A (zh) | 包含nkg2d、cxcr2和dap10/dap12融合多肽的组合物及其使用方法 | |
| WO2025108160A9 (zh) | 多功能基因修饰的免疫细胞及其制备方法和应用 | |
| US20220259281A1 (en) | Chimeric protein expressing t-cells | |
| CN120225665A (zh) | 包含nkg2d、cxcr2和dap10/dap12融合多肽的组合物及其使用方法 | |
| Murakami et al. | Identification and characterization of receptor for cytokine-induced neutrophil chemoattractant-3 on rat neutrophils | |
| CN108997489B (zh) | 干扰素突变体及干扰素突变体融合抗体及其制备方法、应用 | |
| US20240390475A1 (en) | Human papillomavirus vaccines and uses of the same | |
| US20240398926A1 (en) | Novel adenovirus vaccine therapy for the treatment of recurrent respiratory papillomatosis | |
| CA3268631A1 (en) | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof | |
| TW202502821A (zh) | 重組多肽、用以編碼該重組多肽之重組核酸及其於治療癌症的用途 | |
| CN120383663A (zh) | 一种工程化的病毒样颗粒及其在递送基因编辑蛋白中的应用 | |
| Yildirim | New binding activities for interleukin-2 |